



## Principal Investigator Notification:

**From:** Mayo Clinic IRB

**To:** Amy Krambeck

**CC:** [M Childs](#)  
[Amy Krambeck](#)  
[Boyd Viers](#)

**Re:** Continuing Review #: [PR09-006725-04](#)

**Title:** Concurrent radical prostatectomy and urolithiasis management

IRBe Protocol Version: 0.01

IRBe Version Date: 9/29/2009 3:08 PM

IRB Approval Date: 8/21/2013

IRB Expiration Date: 8/20/2014

Continuation of the above referenced study is approved by expedited review procedures (45 CFR 46.110, item 5). The Reviewer determined the research continues to pose no more than minimal risk to subjects. The Reviewer determined that this research continues to satisfy the requirements of 45 CFR 46.111.

AS THE PRINCIPAL INVESTIGATOR OF THIS PROJECT, YOU ARE RESPONSIBLE FOR THE FOLLOWING RELATING TO THIS STUDY:

- 1) When applicable, use only IRB approved materials which are located under the documents tab of the IRBe workspace. Materials include consent forms, HIPAA, questionnaires, contact letters, advertisements, etc.
- 2) Submission to the IRB of any modifications to approved research along with any supporting documents for review and approval prior to initiation of the changes.
- 3) Submission to the IRB of all Unanticipated Problems Involving Risks to Subjects or Others (UPIRISO).
- 4) Compliance with Mayo Clinic Institutional Policies.

Mayo Clinic Institutional Reviewer